Molecular Mechanisms of Ezetimibe-Induced Attenuation of Postprandial Hypertriglyceridemia

被引:40
作者
Sandoval, Jose C. [1 ]
Nakagawa-Toyama, Yumiko [2 ]
Masuda, Daisaku [1 ]
Tochino, Yoshihiro [3 ]
Nakaoka, Hajime [1 ]
Kawase, Ryota [1 ]
Yuasa-Kawase, Miyako [1 ]
Nakatani, Kazuhiro [1 ]
Inagaki, Miwako [1 ]
Tsubakio-Yamamoto, Kazumi [1 ]
Ohama, Tohru [1 ]
Matsuyama, Akifumi [4 ]
Nishida, Makoto [2 ]
Ishigami, Masato [5 ]
Komuro, Issei [1 ]
Yamashita, Shizuya [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Hlth Care Ctr, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan
[4] Fdn Biomed Res & Innovat, Lab Somat Stem Cell Therapy, Kobe, Hyogo, Japan
[5] Osaka Univ, Grad Sch Med, Div Hlth Sci, Dept Biomed Informat, Suita, Osaka 5650871, Japan
关键词
Postprandial hypertriglyceridemia; Ezetimibe; CD36; deficiency; Long-chain fatty acids; Apolipoprotein B-48; ACID TRANSPORT PROTEINS; FATTY-ACIDS; NONFASTING TRIGLYCERIDES; CHOLESTEROL ABSORPTION; ATHEROGENESIS; RISK; HYPERLIPIDEMIA; RESISTANCE; EFFICACY; DISEASE;
D O I
10.5551/jat.4929
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim: Postprandial hypertriglyceridemia (PHTG) has been shown repeatedly to be associated with metabolic syndrome and atherosclerotic cardiovascular diseases. We have recently reported that ezetimibe inhibits PHTG in patients with type IIb hyperlipidemia. Ezetimibe was also reported to attenuate PHTG in combination with low-dose statins in patients with obesity or metabolic syndrome. We reported CD36-deficient (CD36KO) mice as a new model for PHTG, in which the synthesis of chylomicron (CM) in the small intestines is enhanced. In the current study, we investigated the effect of ezetimibe on PHTG in this mouse model of metabolic syndrome. Methods: Wild-type (WT) mice fed a western diet, and CD36KO mice fed a normal chow diet, respectively, were treated for 3 weeks with and without ezetimibe, followed by an evaluation of triglyceride (TG) concentrations by enzymatic method and by high performance liquid chromatography (HPLC) as well as those of and apolipoprotein (Apo) B-48 in plasma and intestinal lymph after oral fat loading with olive oil. Intestinal mucosa was also harvested to evaluate the transcriptional regulation of the genes involved in the intestinal production of ApoB-containing lipoproteins. Results: Ezetimibe dramatically reduced PHTG in both WT and CD36KO mice. HPLC analysis of plasma showed that the decrease in TG content in CM and CM remnants-sized particles contributed to this suppression, suggesting that CM production in the small intestines might be reduced after ezetimibe treatment. Intestinal lymph was collected after oral fat loading in ezetimibe-treated and non-treated mice. Both TG content and ApoB-48 mass were decreased in ezetimibe-treated mice. The quantitative RT-PCR of intestinal mucosa showed down-regulation of the mRNA expression of FATP4 and ApoB in both groups along with FABP2, DGAT1, DGAT2 and SCD1 in WT mice at postprandial state after ezetimibe treatment. Conclusion: Ezetimibe alone reduces PHTG by blocking both the absorption of cholesterol and the intracellular trafficking and metabolism of long-chain fatty acids in enterocytes, resulting in the reduction of the formation of ApoB-48 which is necessary for the ApoB48-containing lipoprotein production in the small intestines.
引用
收藏
页码:914 / 924
页数:11
相关论文
共 31 条
  • [1] Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption
    Altmann, SW
    Davis, HR
    Zhu, LJ
    Yao, XR
    Hoos, LM
    Tetzloff, G
    Iyer, SPN
    Maguire, M
    Golovko, A
    Zeng, M
    Wang, LQ
    Murgolo, N
    Graziano, MP
    [J]. SCIENCE, 2004, 303 (5661) : 1201 - 1204
  • [2] [Anonymous], 2002, CIRCULATION, V106, P3163
  • [3] Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality
    Blanc, V
    Henderson, JO
    Newberry, EP
    Kennedy, S
    Luo, JY
    Davidson, NO
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (16) : 7260 - 7269
  • [4] BOLLMAN JL, 1948, J LAB CLIN MED, V33, P1349
  • [5] Optimization of apolipoprotein B mRNA editing by APOBEC1 apoenzyme and the role of its auxiliary factor, ACF
    Chester, A
    Weinreb, V
    Carter, CW
    Navaratnam, N
    [J]. RNA, 2004, 10 (09) : 1399 - 1411
  • [6] Fatty acid transport proteins and insulin resistance
    Fisher, RM
    Gertow, K
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (02) : 173 - 178
  • [7] Freiberg JJ, 2008, JAMA-J AM MED ASSOC, V300, P2142, DOI [10.1001/jama.2008.621, 10.1002/ana.22384]
  • [8] Remnant Lipoproteins As Strong Key Particles to Atherogenesis
    Fujioka, Yoshio
    Ishikawa, Yuichi
    [J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2009, 16 (03) : 145 - 154
  • [9] The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1
    Ge, Liang
    Wang, Jing
    Qi, Wei
    Miao, Hong-Hua
    Cao, Jian
    Qu, Yu-Xiu
    Li, Bo-Liang
    Song, Bao-Liang
    [J]. CELL METABOLISM, 2008, 7 (06) : 508 - 519
  • [10] CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance
    Goudriaan, JR
    den Boer, MAM
    Rensen, PCN
    Febbraio, M
    Kuipers, F
    Romijn, JA
    Havekes, LM
    Voshol, PJ
    [J]. JOURNAL OF LIPID RESEARCH, 2005, 46 (10) : 2175 - 2181